PBMs Denying Patients Access To Lantus Biosimilars, Says Report
Insulin Glargine Originator Still Has A US Market Share Of Nearly 80%
Biosimilars of insulin glargine have failed to capture significant market share since their launch in 2020 as pharmacy benefit managers favor the originator’s higher list price for its associated rebates, according to a report from the Biosimilars Council.
